
THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:


1. Use of ledipasvir and sofosbuvir in the preparation of a medicament for treating a patient with hepatitis C virus infection wherein the medicament is in the form of a fixed dose combination tablet comprising:

a) from about 10% to about 25% w/w of a solid dispersion comprising ledipasvir dispersed within a polymer matrix formed by copovidone, wherein the weight ratio of ledipasvir to copovidone in the solid dispersion is about 1:1 and wherein the ledipasvir is substantially amorphous and has the formula:



;

b) from about 35% to about 45% w/w of sofosbuvir, wherein sofosbuvir is substantially crystalline, wherein the crystalline sofosbuvir has XRPD 2θ-reflections (° ± 0.2θ) at: 6.1 and 12.7 and 20.8 and wherein sofosbuvir has the formula:



;

c) from about 5.0% to about 25% w/w of lactose monohydrate;

d) from about 5.0% to about 25% w/w of microcrystalline cellulose;

e) from about 1.0% to about 10% w/w of croscarmellose sodium;

f) from about 0.5% to about 3% w/w of colloidal silicon dioxide; and

g) from about 0.1% to about 3% w/w of magnesium stearate.

2. The use of claim 1, comprising about 40% w/w of sofosbuvir.

3. The use of claim 1 or 2, comprising about 18% w/w of the solid dispersion comprising ledipasvir.

4. The use of claim 1 having from about 50 mg to about 130 mg of ledipasvir and from about 300 mg to about to 600 mg of sofosbuvir.

5. The use of claim 4 having 90 mg of ledipasvir and about 400 mg of sofosbuvir.

6. The use of claim 1 comprising

a) about 18% w/w of the solid dispersion comprising ledipasvir;

b) about 40% w/w of sofosbuvir;

c) about 16.5% w/w of lactose monohydrate;

d) about 18.0% w/w of microcrystalline cellulose;


e) about 5.0% w/w of croscarmellose sodium;

f) about 1.0% w/w of colloidal silicon dioxide; and


g) about 1.5% w/w of magnesium stearate.

7. Use of ledipasvir and sofosbuvir in the preparation of a medicament for treating a patient with hepatitis C virus infection, wherein the medicament is in the form of a fixed dose combination tablet comprising:

a) about 180 mg of a solid dispersion comprising ledipasvir dispersed within a polymer matrix formed by copovidone, wherein the weight ratio of ledipasvir to copovidone in the solid dispersion is about 1:1 and wherein ledipasvir is substantially amorphous and has the formula:



b) about 400 mg of sofosbuvir, wherein sofosbuvir is substantially crystalline, wherein the crystalline sofosbuvir has XRPD 2θ-reflections (° ± 0.2θ) at: 6.1 and 12.7 and 20.8 and wherein sofosbuvir has the formula:



;

c) about 165 mg of lactose monohydrate;

d) about 180 mg of microcrystalline cellulose;


e) about 50 mg of croscarmellose sodium;

f) about 10 mg of colloidal silicon dioxide; and

g) about 15 mg of magnesium stearate.


8. Use of ledipasvir and sofosbuvir in the preparation of a medicament for treating a patient with hepatitis C virus infection, wherein the medicament is in the form of a fixed dose combination tablet comprising:

a) about 90 mg of a solid dispersion comprising ledipasvir dispersed within a polymer matrix formed by copovidone, wherein the weight ratio of ledipasvir to copovidone in the solid dispersion is about 1:1 and wherein ledipasvir is substantially amorphous and has the formula:



;

b) about 400 mg of sofosbuvir, wherein sofosbuvir is substantially crystalline, wherein the crystalline sofosbuvir has XRPD 2θ-reflections (° ± 0.2θ) at: 6.1 and 12.7 and 20.8 and wherein sofosbuvir has the formula:



;

c) about 165 mg of lactose monohydrate;

d) about 180 mg of microcrystalline cellulose;

e) about 50 mg of croscarmellose sodium;

f) about 10 mg of colloidal silicon dioxide; and

g) about 15 mg of magnesium stearate.

9. The use of claim 7 or 8 further comprising a film coating.